Apixaban + Enoxaparin |
X |
F |
Apixaban may enhance the anticoagulant
effect of enoxaparin |
Avoid concomitant use |
Carvedilol + Ipratropium Bromide/Salbutamol |
X |
F |
Beta-blockers
(nonselective) may diminish the bronchodilatory effect of beta2-agonists |
Avoid combination or monitor for diminished bronchodilatory effects of
the beta2-agonist |
Clarithromycin + Lopinavir/Ritonavir |
X |
F |
Clarithromycin may
increase the serum concentration of lopinavir/ritonavir, increase
QT-prolongation effects |
Avoid combination or monitor for QTc interval
prolongation and arrhythmias |
Ipratropium Bromide + Diphenhydramine |
X |
F |
Increase the
anticholinergic effects |
Avoid combination or monitor for
anticholinergic related toxicity |
Lopinavir/Ritonavir + Amiodarone |
X |
F |
CYP3A43
inhibitors may increase the serum concentration of amiodarone, increase
QT- prolongation effect |
Avoid combination or monitor for amiodarone
toxicity and QTc interval prolongation |
Lopinavir/Ritonavir + Rivaroxaban |
X |
G |
P-glycoprotein and CYP3A4
inhibitors may increase the serum concentration of rivaroxaban. |
Avoid
combination or monitor for adverse effects |
Rifampin + Lopinavir/Ritonavir |
X |
G |
Rifampin may decrease the serum
concentration of lopinavir/ritonavir. |
Avoid combination |
Salmetrol + Fluticasone /Salmeterol |
X |
F |
Synergism effects of
beta2-agonists (long-acting) |
Avoid combination |
Sertraline + Selegiline |
X |
F |
Selective serotonin reuptake
inhibitors may enhance the serotonergic effect of selegiline |
Avoid
combination |
Amiodarone + Azithromycin |
D |
F |
Increase QT-prolongation effects |
Consider alternatives to this combination, monitor for QTc interval
prolongation and arrhythmias |
Amiodarone + Digoxin |
D |
E |
Amiodarone may increase the serum
concentration of digoxin |
Reduce the digoxin dose (30% to 50%) or the
dosing frequency, monitor digoxin levels |
Alprazolam + Oxycodone |
D |
F |
Increase CNS depressant effects |
Close
monitoring for adverse effects |
Atracurium + Dexamethasone |
D |
E |
Neuromuscular-blocking agents
(nondepolarizing) may enhance the adverse neuromuscular effect of
corticosteroids |
Administer the lowest possible doses, limit duration
of administration, monitor closely for sign and symptom of myopathy or
neuropathy |
Atracurium + Hydrocortisone |
D |
E |
Neuromuscular-blocking agents
(nondepolarizing) may enhance the adverse neuromuscular effect of
corticosteroids |
Administer the lowest possible doses, limit duration
of administration, monitor closely for sign and symptom of myopathy or
neuropathy |
Calcium Carbonate + Levofloxacin |
D |
E |
Oral calcium salts may
decrease the absorption of oral quinolones |
Separate the doses by at
least 2 hours |
Calcium Carbonate + Levothyroxine |
D |
F |
Oral calcium salts may
decrease the absorption of thyroid products |
Separate the doses by at
least 4 hours |
Carbamazepine + Alprazolam |
D |
F |
CYP3A4 inducers may decrease the
serum concentration of alprazolam |
Consider using an alternative or a
dosage adjustment |
Celecoxib + Enoxaparin |
D |
F |
NSAIDs4 may enhance
the anticoagulant effect of enoxaparin |
Monitor closely for signs and
symptoms of bleeding |
Citalopram + Enoxaparin |
D |
F |
Agents with antiplatelet effects may
enhance the anticoagulant effect of Enoxaparin |
Monitor closely for
signs and symptoms of bleeding |
Citalopram + Heparin |
D |
F |
Antiplatelet agents may enhance the
anticoagulant effect of heparin |
Decrease the dose of heparin or
citalopram |
Citalopram + Ibuprofen |
D |
G |
Selective serotonin reuptake inhibitors
may enhance the antiplatelet effect of ibuprofen |
Monitor patients for
evidence of bleeding |
Chlorpromazine + Azithromycin |
D |
F |
Increase QT-prolongation effect |
Consider alternatives to this combination or monitor for QTc interval
prolongation and arrhythmias |
Diltiazem +Atorvastatin |
D |
F |
Diltiazem may increase the serum
concentration of atorvastatin |
Administer lower doses of atorvastatin,
monitor for signs of atorvastatin toxicity |
Fluvoxamine + Heparin |
D |
F |
Agents with antiplatelet effects may
enhance the anticoagulant effect of heparin |
Decrease the dose of
heparin or antiplatelet agent |
Lopinavir/Ritonavir + Apixaban |
D |
G |
P-glycoprotein and CYP3A4
inhibitors may increase the serum concentration of apixaban |
Administer
50% of the usual dose of apixaban |
Lopinavir/Ritonavir + Colchicine |
D |
G |
P-glycoprotein and CYP3A4
inhibitors may increase the serum concentration of colchicine |
Reduce
the daily dosage or dose frequency and monitor closely |
Lopinavir/Ritonavir + Diltiazem |
D |
G |
CYP3A4 inhibitors may increase
the serum concentration of diltiazem |
Consider using an alternative or
monitor for toxicity of calcium channel blockers, a 50% dose reduction
may be required |
Lopinavir/Ritonavir + Isosorbide Dinitrate |
D |
F |
CYP3A4 inhibitors
may increase the serum concentration of isosorbide dinitrate |
Monitor
for increased adverse effects of isosorbide dinitrate |
Lopinavir/Ritonavir + Lidocaine |
D |
F |
CYP3A4 inhibitors may increase
the serum concentration of lidocaine |
Monitor for increased adverse
effects of lidocaine |
Morphine + Clopidogrel |
D |
F |
Morphine may decrease the serum
concentration of antiplatelet agents |
The clinical risk associated with
this interaction has not been fully investigated, administration an
alternative may be considered |
Morphine + Fentanyl |
D |
F |
Increase CNS depressant effects |
Close
monitoring for adverse effects |
Midazolam + Morphine |
D |
F |
Increase CNS depressant effects |
Close
monitoring for adverse effects |
Rifampin + Clarithromycin |
D |
G |
CYP3A4 inducers may decrease the
serum concentration of clarithromycin |
Consider an alternative
antimicrobial therapy |
Propofol + Morphine |
D |
F |
Increase CNS depressant effects |
Close
monitoring for adverse effects |
Rifampin + Pantoprazole |
D |
F |
CYP2C19 inducers may decrease the
serum concentration pantoprazole |
Consider using an alternative or
monitor for decreased effects of pantoprazole |